{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:17:52Z","timestamp":1787505472521,"version":"build-2736575974"},"reference-count":180,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1038\/s41574-022-00780-6","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T09:03:00Z","timestamp":1670576580000},"page":"217-231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Sex hormones in SARS-CoV-2 susceptibility: key players or confounders?"],"prefix":"10.1038","volume":"19","author":[{"given":"Nicola","family":"Lott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E.","family":"Gebhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Bengs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5204-4473","authenticated-orcid":false,"given":"Achi","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela M.","family":"Kuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3566-3467","authenticated-orcid":false,"given":"Vera","family":"Regitz-Zagrosek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7240-5822","authenticated-orcid":false,"given":"Catherine","family":"Gebhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"key":"780_CR1","doi-asserted-by":"crossref","first-page":"L219","DOI":"10.1152\/ajplung.00332.2020","volume":"321","author":"Q Ma","year":"2021","unstructured":"Ma, Q., Hao, Z. W. & Wang, Y. F. The effect of estrogen in coronavirus disease 2019 (COVID-19). Am. J. Physiol. Lung Cell Mol. Physiol. 321, L219\u2013L227 (2021).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"780_CR2","volume":"16","author":"MS Green","year":"2021","unstructured":"Green, M. S., Nitzan, D., Schwartz, N., Niv, Y. & Peer, V. Sex differences in the case-fatality rates for COVID-19 \u2014 A comparison of the age-related differences and consistency over seven countries. PLoS One 16, e0250523 (2021).","journal-title":"PLoS One"},{"key":"780_CR3","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41591-021-01292-y","volume":"27","author":"CH Sudre","year":"2021","unstructured":"Sudre, C. H. et al. Attributes and predictors of long COVID. Nat. Med. 27, 626\u2013631 (2021).","journal-title":"Nat. Med."},{"key":"780_CR4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13293-020-00304-9","volume":"11","author":"C Gebhard","year":"2020","unstructured":"Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H. K., Morgan, R. & Klein, S. L. Impact of sex and gender on COVID-19 outcomes in Europe. Biol. Sex. Differ. 11, 29 (2020).","journal-title":"Biol. Sex. Differ."},{"key":"780_CR5","doi-asserted-by":"crossref","first-page":"114716","DOI":"10.1016\/j.socscimed.2022.114716","volume":"294","author":"AC Danielsen","year":"2022","unstructured":"Danielsen, A. C. et al. Sex disparities in COVID-19 outcomes in the United States: quantifying and contextualizing variation. Soc. Sci. Med. 294, 114716 (2022).","journal-title":"Soc. Sci. Med."},{"key":"780_CR6","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1038\/s41586-021-03644-7","volume":"597","author":"H Shattuck-Heidorn","year":"2021","unstructured":"Shattuck-Heidorn, H. et al. A finding of sex similarities rather than differences in COVID-19 outcomes. Nature 597, E7\u2013E9 (2021).","journal-title":"Nature"},{"key":"780_CR7","doi-asserted-by":"crossref","first-page":"27285","DOI":"10.1073\/pnas.2012520117","volume":"117","author":"V Galasso","year":"2020","unstructured":"Galasso, V. et al. Gender differences in COVID-19 attitudes and behavior: panel evidence from eight countries. Proc. Natl Acad. Sci. USA 117, 27285\u201327291 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"780_CR8","first-page":"1168","volume":"395","author":"The Lancet.","year":"2020","unstructured":"The Lancet. The gendered dimensions of COVID-19. Lancet 395, 1168 (2020).","journal-title":"Lancet"},{"key":"780_CR9","doi-asserted-by":"crossref","first-page":"E1041","DOI":"10.1503\/cmaj.200971","volume":"192","author":"CP Tadiri","year":"2020","unstructured":"Tadiri, C. P. et al. The influence of sex and gender domains on COVID-19 cases and mortality. Can. Med. Assoc. J. 192, E1041\u2013E1045 (2020).","journal-title":"Can. Med. Assoc. J."},{"key":"780_CR10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","journal-title":"Cell"},{"key":"780_CR11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281\u2013292.e6 (2020).","journal-title":"Cell"},{"key":"780_CR12","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20209610","volume":"16","author":"F Hikmet","year":"2020","unstructured":"Hikmet, F. et al. The protein expression profile of ACE2 in human tissues. Mol. Syst. Biol. 16, e9610 (2020).","journal-title":"Mol. Syst. Biol."},{"key":"780_CR13","volume":"21","author":"G Ryu","year":"2021","unstructured":"Ryu, G. & Shin, H. W. SARS-CoV-2 infection of airway epithelial cells. Immune Netw. 21, e3 (2021).","journal-title":"Immune Netw."},{"key":"780_CR14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","volume":"182","author":"YJ Hou","year":"2020","unstructured":"Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182, 429\u2013446.e414 (2020).","journal-title":"Cell"},{"key":"780_CR15","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.3390\/v13091715","volume":"13","author":"L Guti\u00e9rrez-Chamorro","year":"2021","unstructured":"Guti\u00e9rrez-Chamorro, L. et al. SARS-CoV-2 infection modulates ACE2 function and subsequent inflammatory responses in swabs and plasma of COVID-19 patients. Viruses 13, 1715 (2021).","journal-title":"Viruses"},{"key":"780_CR16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","volume":"203","author":"I Hamming","year":"2004","unstructured":"Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203, 631\u2013637 (2004).","journal-title":"J. Pathol."},{"key":"780_CR17","doi-asserted-by":"crossref","DOI":"10.15252\/embj.20105114","volume":"39","author":"S Lukassen","year":"2020","unstructured":"Lukassen, S. et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 39, e105114 (2020).","journal-title":"EMBO J."},{"key":"780_CR18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11481-020-09979-8","volume":"16","author":"RK Paidi","year":"2021","unstructured":"Paidi, R. K. et al. ACE-2-interacting domain of SARS-CoV-2 (AIDS) peptide suppresses inflammation to reduce fever and protect lungs and heart in mice: implications for COVID-19 Therapy. J. Neuroimmune Pharmacol. 16, 59\u201370 (2021).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"780_CR19","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/infdis\/jiaa332","volume":"222","author":"BGG Pinto","year":"2020","unstructured":"Pinto, B. G. G. et al. ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19. J. Infect. Dis. 222, 556\u2013563 (2020).","journal-title":"J. Infect. Dis."},{"key":"780_CR20","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1001\/jama.2020.8707","volume":"323","author":"S Bunyavanich","year":"2020","unstructured":"Bunyavanich, S., Do, A. & Vicencio, A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA 323, 2427\u20132429 (2020).","journal-title":"JAMA"},{"key":"780_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2020.05.013","volume":"18","author":"N Saheb Sharif-Askari","year":"2020","unstructured":"Saheb Sharif-Askari, N. et al. Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD. Mol. Ther. Methods Clin. Dev. 18, 1\u20136 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"780_CR22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112\u2013116 (2005).","journal-title":"Nature"},{"key":"780_CR23","doi-asserted-by":"crossref","first-page":"111254","DOI":"10.1016\/j.mce.2021.111254","volume":"529","author":"E Cantero-Navarro","year":"2021","unstructured":"Cantero-Navarro, E. et al. Renin-angiotensin system and inflammation update. Mol. Cell. Endocrinol. 529, 111254 (2021).","journal-title":"Mol. Cell. Endocrinol."},{"key":"780_CR24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/CIRCULATIONAHA.120.047049","volume":"142","author":"K Wang","year":"2020","unstructured":"Wang, K., Gheblawi, M. & Oudit, G. Y. Angiotensin converting enzyme 2: a double-edged sword. Circulation 142, 426\u2013428 (2020).","journal-title":"Circulation"},{"key":"780_CR25","doi-asserted-by":"crossref","first-page":"L84","DOI":"10.1152\/ajplung.00071.2009","volume":"297","author":"HP Jia","year":"2009","unstructured":"Jia, H. P. et al. Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am. J. Physiol. Lung Cell Mol. Physiol. 297, L84\u2013L96 (2009).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"780_CR26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271066","volume":"17","author":"RH Shoemaker","year":"2022","unstructured":"Shoemaker, R. H. et al. Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer. PLoS One 17, e0271066 (2022).","journal-title":"PLoS One"},{"key":"780_CR27","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05065645 (2022)."},{"key":"780_CR28","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04335136 (2021)."},{"key":"780_CR29","unstructured":"Apeiron Biologics. APEIRON\u2019s APN01 Shows Clinical Benefits for Severely Ill COVID-19 Patients in Phase 2 Trial https:\/\/www.apeiron-biologics.com\/apeirons-apn01-shows-clinical-benefits-for-severely-ill-covid-19-patients-in-phase-2-trial\/ (2021)."},{"key":"780_CR30","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/2159-8290.CD-13-1010","volume":"4","author":"J Lucas","year":"2014","unstructured":"Lucas, J. et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 4, 1310\u20131325 (2014).","journal-title":"Cancer Discov."},{"key":"780_CR31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","volume":"310","author":"SA Tomlins","year":"2005","unstructured":"Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644\u2013648 (2005).","journal-title":"Science"},{"key":"780_CR32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90491-1","volume":"11","author":"M Baratchian","year":"2021","unstructured":"Baratchian, M. et al. Androgen regulation of pulmonary AR, TMPRSS2 and ACE2 with implications for sex-discordant COVID-19 outcomes. Sci. Rep. 11, 11130 (2021).","journal-title":"Sci. Rep."},{"key":"780_CR33","volume":"6","author":"AD Rossi","year":"2021","unstructured":"Rossi, A. D., Araujo, J. L. Fd, Almeida, T. B. D. & Ribereiro-Alves, M. Association between ACE2 and TMPRSS2 nasopharyngeal expression and COVID-19 respiratory distress. Sci. Rep. 6, 9658 (2021).","journal-title":"Sci. Rep."},{"key":"780_CR34","doi-asserted-by":"crossref","first-page":"103255","DOI":"10.1016\/j.ebiom.2021.103255","volume":"65","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann, M. et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine 65, 103255 (2021).","journal-title":"EBioMedicine"},{"key":"780_CR35","doi-asserted-by":"crossref","first-page":"e00754-20","DOI":"10.1128\/AAC.00754-20","volume":"64","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob. Agents Chemother. 64, e00754-20 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"780_CR36","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2108728118","volume":"118","author":"M Mahoney","year":"2021","unstructured":"Mahoney, M. et al. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Proc. Natl Acad. Sci. USA 118, e2108728118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"780_CR37","volume":"12","author":"K Li","year":"2021","unstructured":"Li, K., Meyerholz, D. K., Bartlett, J. A. & McCray, P. B. Jr The TMPRSS2 inhibitor nafamostat reduces SARS-CoV-2 pulmonary infection in mouse models of COVID-19. mBio 12, e0097021 (2021).","journal-title":"mBio"},{"key":"780_CR38","doi-asserted-by":"publisher","DOI":"10.1101\/2022.01.28.22270035","author":"G Chupp","year":"2022","unstructured":"Chupp, G. et al. A phase 2 randomized, double-blind, placebo-controlled trial of oral camostat mesylate for early treatment of COVID-19 outpatients showed shorter illness course and attenuation of loss of smell and taste. medRxiv https:\/\/doi.org\/10.1101\/2022.01.28.22270035 (2022).","journal-title":"medRxiv"},{"key":"780_CR39","doi-asserted-by":"crossref","first-page":"101169","DOI":"10.1016\/j.eclinm.2021.101169","volume":"41","author":"SV Zhuravel","year":"2021","unstructured":"Zhuravel, S. V., Khmelnitskiy, O. K., Birlaka, O. O., Gritsan, A. I. & Goloshchekin, B. M. Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial. EClinicalMedicine 41, 101169 (2021).","journal-title":"EClinicalMedicine"},{"key":"780_CR40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00439-011-1011-z","volume":"130","author":"JB Berletch","year":"2011","unstructured":"Berletch, J. B., Yang, F., Xu, J., Carrel, L. & Disteche, C. M. Genes that escape from X inactivation. Hum. Genet. 130, 237\u2013245 (2011).","journal-title":"Hum. Genet."},{"key":"780_CR41","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nature24265","volume":"550","author":"T Tukiainen","year":"2017","unstructured":"Tukiainen, T. et al. Landscape of X chromosome inactivation across human tissues. Nature 550, 244\u2013248 (2017).","journal-title":"Nature"},{"key":"780_CR42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/HJH.0b013e328332b88d","volume":"28","author":"A Milsted","year":"2010","unstructured":"Milsted, A. et al. Regulation of multiple renin-angiotensin system genes by Sry. J. Hypertens. 28, 59\u201364 (2010).","journal-title":"J. Hypertens."},{"key":"780_CR43","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.3892\/mmr.2017.6460","volume":"15","author":"R Fan","year":"2017","unstructured":"Fan, R. et al. Preliminary analysis of the association between methylation of the ACE2 promoter and essential hypertension. Mol. Med. Rep. 15, 3905\u20133911 (2017).","journal-title":"Mol. Med. Rep."},{"key":"780_CR44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40249-020-00662-x","volume":"9","author":"MY Li","year":"2020","unstructured":"Li, M. Y., Li, L., Zhang, Y. & Wang, X. S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect. Dis. Poverty 9, 45 (2020).","journal-title":"Infect. Dis. Poverty"},{"key":"780_CR45","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.mayocp.2020.06.018","volume":"95","author":"LB Baughn","year":"2020","unstructured":"Baughn, L. B. et al. Targeting TMPRSS2 in SARS-CoV-2 Infection. Mayo Clin. Proc. 95, 1989\u20131999 (2020).","journal-title":"Mayo Clin. Proc."},{"key":"780_CR46","volume":"118","author":"Y Qiao","year":"2021","unstructured":"Qiao, Y. et al. Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2. Proc. Natl Acad. Sci. 118, e2021450118 (2021).","journal-title":"Proc. Natl Acad. Sci."},{"key":"780_CR47","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41591-020-01227-z","volume":"27","author":"C Muus","year":"2021","unstructured":"Muus, C. et al. Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics. Nat. Med. 27, 546\u2013559 (2021).","journal-title":"Nat. Med."},{"key":"780_CR48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2020.04.065","volume":"78","author":"H Song","year":"2020","unstructured":"Song, H., Seddighzadeh, B., Cooperberg, M. R. & Huang, F. W. Expression of ACE2, the SARS-CoV-2 receptor, and TMPRSS2 in prostate epithelial cells. Eur. Urol. 78, 296\u2013298 (2020).","journal-title":"Eur. Urol."},{"key":"780_CR49","doi-asserted-by":"crossref","first-page":"L843","DOI":"10.1152\/ajplung.00391.2020","volume":"319","author":"RSR Kalidhindi","year":"2020","unstructured":"Kalidhindi, R. S. R. et al. Sex steroids skew ACE2 expression in human airway: a contributing factor to sex differences in COVID-19? Am. J. Physiol. Lung Cell. Mol. Physiol. 319, L843\u2013L847 (2020).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"780_CR50","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/cvr\/cvaa191","volume":"116","author":"H Liu","year":"2020","unstructured":"Liu, H. et al. Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart. Cardiovasc. Res. 116, 1733\u20131741 (2020).","journal-title":"Cardiovasc. Res."},{"key":"780_CR51","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fendo.2013.00201","volume":"4","author":"MC Chappell","year":"2014","unstructured":"Chappell, M. C., Marshall, A. C., Alzayadneh, E. M., Shaltout, H. A. & Diz, D. I. Update on the Angiotensin converting enzyme 2-Angiotensin (1-7)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways. Front. Endocrinol. 4, 201 (2014).","journal-title":"Front. Endocrinol."},{"key":"780_CR52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13293-019-0247-5","volume":"10","author":"MC White","year":"2019","unstructured":"White, M. C., Fleeman, R. & Arnold, A. C. Sex differences in the metabolic effects of the renin-angiotensin system. Biol. Sex. Dif. 10, 31 (2019).","journal-title":"Biol. Sex. Dif."},{"key":"780_CR53","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2042-6410-1-6","volume":"1","author":"J Liu","year":"2010","unstructured":"Liu, J. et al. Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17beta-oestradiol-dependent and sex chromosome-independent. Biol. Sex. Differ. 1, 6 (2010).","journal-title":"Biol. Sex. Differ."},{"key":"780_CR54","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/ATVBAHA.112.248559","volume":"32","author":"M Gupte","year":"2012","unstructured":"Gupte, M. et al. Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL\/6 mice. Arterioscler. Thromb. Vasc. Biol. 32, 1392\u20131399 (2012).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"780_CR55","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13293-017-0128-8","volume":"8","author":"A Fernandez-Atucha","year":"2017","unstructured":"Fernandez-Atucha, A. et al. Sex differences in the aging pattern of renin-angiotensin system serum peptidases. Biol. Sex. Differ. 8, 5 (2017).","journal-title":"Biol. Sex. Differ."},{"key":"780_CR56","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-020-02942-2","volume":"24","author":"P Sw\u00e4rd","year":"2020","unstructured":"Sw\u00e4rd, P. et al. Age and sex differences in soluble ACE2 may give insights for COVID-19. Crit. Care 24, 221 (2020).","journal-title":"Crit. Care"},{"key":"780_CR57","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1161\/CIRCULATIONAHA.120.049007","volume":"142","author":"CP Nelson","year":"2020","unstructured":"Nelson, C. P. et al. Genetic associations with plasma angiotensin converting enzyme 2 concentration. Circulation 142, 1117\u20131119 (2020).","journal-title":"Circulation"},{"key":"780_CR58","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/1440-1681.12069","volume":"40","author":"SK Patel","year":"2013","unstructured":"Patel, S. K., Velkoska, E. & Burrell, L. M. Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in. Clin. Exp. Pharmacol. Physiol. 40, 551\u2013559 (2013).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"780_CR59","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/HJH.0b013e32834f04b6","volume":"30","author":"A Soro-Paavonen","year":"2012","unstructured":"Soro-Paavonen, A. et al. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J. Hypertens. 30, 375\u2013383 (2012).","journal-title":"J. Hypertens."},{"key":"780_CR60","volume":"19","author":"J Chen","year":"2020","unstructured":"Chen, J. et al. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging Cell 19, e13168 (2020).","journal-title":"Aging Cell"},{"key":"780_CR61","volume":"53","author":"JM Masteron","year":"2021","unstructured":"Masteron, J. M. et al. Feminising hormone therapy reduces testicular ACE-2 receptor expression: implications for treatment or prevention of COVID-19 infection in men. Andrologica 53, e14186 (2021).","journal-title":"Andrologica"},{"key":"780_CR62","volume":"11","author":"S Bengs","year":"2021","unstructured":"Bengs, S. et al. Immunoreactivity of the SARS-CoV-2 entry proteins ACE-2 and TMPRSS-2 in murine models of hormonal manipulation, ageing, and cardiac injury. Sci. Rep. 11, 23993 (2021).","journal-title":"Sci. Rep."},{"key":"780_CR63","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.stem.2020.11.009","volume":"27","author":"RM Samuel","year":"2020","unstructured":"Samuel, R. M. et al. Androgen signaling regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men. Cell Stem Cell 27, 876\u2013889.e812 (2020).","journal-title":"Cell Stem Cell"},{"key":"780_CR64","doi-asserted-by":"crossref","first-page":"11508","DOI":"10.3390\/ijms222111508","volume":"22","author":"JA Aguilar-Pineda","year":"2021","unstructured":"Aguilar-Pineda, J. A. et al. Structural and functional analysis of female sex hormones against SARS-CoV-2 cell entry. Int. J. Mol. Sci. 22, 11508 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"780_CR65","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0008-6363(01)00479-5","volume":"53","author":"M Fischer","year":"2002","unstructured":"Fischer, M., Baessler, A. & Schunkert, H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc. Res. 53, 672\u2013677 (2002).","journal-title":"Cardiovasc. Res."},{"key":"780_CR66","volume":"9","author":"RMR Lemes","year":"2021","unstructured":"Lemes, R. M. R. et al. 17\u03b2-estradiol reduces SARS-CoV-2 infection in vitro. Physiol. Rep. 9, e14707 (2021).","journal-title":"Physiol. Rep."},{"key":"780_CR67","doi-asserted-by":"crossref","first-page":"L1280","DOI":"10.1152\/ajplung.00153.2020","volume":"318","author":"KE Stelzig","year":"2020","unstructured":"Stelzig, K. E. et al. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 318, L1280\u2013L1281 (2020).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"780_CR68","volume":"19","author":"J Peng","year":"2021","unstructured":"Peng, J. et al. Age and gender differences in ACE2 and TMPRSS2 expressions in oral epithelial cells. J. Transl. Med. 19, 358 (2021).","journal-title":"J. Transl. Med."},{"key":"780_CR69","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1002\/jmv.26045","volume":"92","author":"J Song","year":"2020","unstructured":"Song, J. et al. Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS-CoV-2. J. Med. Virol. 92, 2556\u20132566 (2020).","journal-title":"J. Med. Virol."},{"key":"780_CR70","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.mce.2009.12.022","volume":"317","author":"L Mikkonen","year":"2010","unstructured":"Mikkonen, L., Pihlajamaa, P., Sahu, B., Zhang, F. P. & J\u00e4nne, O. A. Androgen receptor and androgen-dependent gene expression in lung. Mol. Cell Endocrinol. 317, 14\u201324 (2010).","journal-title":"Mol. Cell Endocrinol."},{"key":"780_CR71","volume":"12","author":"DA Leach","year":"2021","unstructured":"Leach, D. A. et al. The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells. Nat. Commun. 12, 4068 (2021).","journal-title":"Nat. Commun."},{"key":"780_CR72","doi-asserted-by":"crossref","first-page":"102254","DOI":"10.1016\/j.isci.2021.102254","volume":"24","author":"Q Deng","year":"2021","unstructured":"Deng, Q., Rasool, R. U., Russell, R. M., Natesan, R. & Asangani, I. A. Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19. iScience 24, 102254 (2021).","journal-title":"iScience"},{"key":"780_CR73","volume":"12","author":"F Li","year":"2021","unstructured":"Li, F., Han, M., Dai, P., He, J. & Tao, X. Distinct mechanisms for TMPRSS2 expressionexplain organ-specific inhibition of SARS-CoV-2infection by enzalutamide. Nat. Commun. 12, 866 (2021).","journal-title":"Nat. Commun."},{"key":"780_CR74","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/jnci\/djn150","volume":"100","author":"SR Setlur","year":"2008","unstructured":"Setlur, S. R. et al. Estrogen-dependent signaling in the molecularrly distinct subclass of agressive prostate cancer. J. Natl Cancer Inst. 100, 815\u2013825 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"780_CR75","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00436-003-0943-1","volume":"91","author":"J Boissier","year":"2003","unstructured":"Boissier, J., Chlichlia, K., Digon, Y., Ruppel, A. & Mone, H. Preliminary study on sex-related inflammatory reactions in mice infected with Schistosoma mansoni. Parasitol. Res. 91, 144\u2013150 (2003).","journal-title":"Parasitol. Res."},{"key":"780_CR76","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/cmi.2009.55","volume":"6","author":"HJ Xia","year":"2009","unstructured":"Xia, H. J., Zhang, G. H., Wang, R. R. & Zheng, Y. T. The influence of age and sex on the cell counts of peripheral blood leukocyte subpopulations in Chinese rhesus macaques. Cell Mol. Immunol. 6, 433\u2013440 (2009).","journal-title":"Cell Mol. Immunol."},{"key":"780_CR77","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1165\/rcmb.2009-0016OC","volume":"42","author":"BN Melgert","year":"2010","unstructured":"Melgert, B. N. et al. Macrophages: regulators of sex differences in asthma? Am. J. Respir. Cell Mol. Biol. 42, 595\u2013603 (2010).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"780_CR78","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/gene.2009.12","volume":"10","author":"A Hewagama","year":"2009","unstructured":"Hewagama, A., Patel, D., Yarlagadda, S., Strickland, F. M. & Richardson, B. C. Stronger inflammatory\/cytotoxic T-cell response in women identified by microarray analysis. Genes. Immun. 10, 509\u2013516 (2009).","journal-title":"Genes. Immun."},{"key":"780_CR79","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/2141224a0","volume":"214","author":"M Butterworth","year":"1967","unstructured":"Butterworth, M., McClellan, B. & Allansmith, M. Influence of sex in immunoglobulin levels. Nature 214, 1224\u20131225 (1967).","journal-title":"Nature"},{"key":"780_CR80","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1016\/j.vaccine.2008.04.054","volume":"26","author":"IF Cook","year":"2008","unstructured":"Cook, I. F. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 26, 3551\u20133555 (2008).","journal-title":"Vaccine"},{"key":"780_CR81","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10522-008-9138-6","volume":"9","author":"A Wikby","year":"2008","unstructured":"Wikby, A., Mansson, I. A., Johansson, B., Strindhall, J. & Nilsson, S. E. The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20-100 years of age. Biogerontology 9, 299\u2013308 (2008).","journal-title":"Biogerontology"},{"key":"780_CR82","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.humimm.2004.02.021","volume":"65","author":"MC Villacres","year":"2004","unstructured":"Villacres, M. C., Longmate, J., Auge, C. & Diamond, D. J. Predominant type 1 CMV-specific memory T-helper response in humans: evidence for gender differences in cytokine secretion. Hum. immunol. 65, 476\u2013485 (2004).","journal-title":"Hum. immunol."},{"key":"780_CR83","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/nm1295-1279","volume":"1","author":"A Amadori","year":"1995","unstructured":"Amadori, A. et al. Genetic control of the CD4\/CD8 T-cell ratio in humans. Nat. Med. 1, 1279\u20131283 (1995).","journal-title":"Nat. Med."},{"key":"780_CR84","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4103\/0019-5359.42725","volume":"62","author":"BR Das","year":"2008","unstructured":"Das, B. R. et al. Reference ranges for lymphocyte subsets in adults from western India: influence of sex, age and method of enumeration. Indian J. Med. Sci. 62, 397\u2013406 (2008).","journal-title":"Indian J. Med. Sci."},{"key":"780_CR85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yfrne.2008.11.001","volume":"30","author":"AP Arnold","year":"2009","unstructured":"Arnold, A. P. & Chen, X. What does the \u201cfour core genotypes\u201d mouse model tell us about sex differences in the brain and other tissues? Front. Neuroendocrinol. 30, 1\u20139 (2009).","journal-title":"Front. Neuroendocrinol."},{"key":"780_CR86","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1517\/14712598.8.11.1659","volume":"8","author":"GA Poland","year":"2008","unstructured":"Poland, G. A., Ovsyannikova, I. G. & Jacobson, R. M. Personalized vaccines: the emerging field of vaccinomics. Expert Opin. Biol. Ther. 8, 1659\u20131667 (2008).","journal-title":"Expert Opin. Biol. Ther."},{"key":"780_CR87","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-14396-9","volume":"11","author":"EJ M\u00e1rquez","year":"2020","unstructured":"M\u00e1rquez, E. J. et al. Sexual-dimorphism in human immune system aging. Nat. Commun. 11, 751 (2020).","journal-title":"Nat. Commun."},{"key":"780_CR88","doi-asserted-by":"crossref","unstructured":"Kovats, S., Carreras, E. & Agrawal, H. In Sex Hormones and Immunity to Infection (eds Klein, S. L. & Roberts, C. W.) 53\u201392 (Springer-Verlag, 2010).","DOI":"10.1007\/978-3-642-02155-8_3"},{"key":"780_CR89","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.yhbeh.2016.11.017","volume":"88","author":"J Roved","year":"2017","unstructured":"Roved, J., Westerdahl, H. & Hasselquist, D. Sex differences in immune responses: hormonal effects, antagonistic selection, and evolutionary consequences. Horm. Behav. 88, 95\u2013105 (2017).","journal-title":"Horm. Behav."},{"key":"780_CR90","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cellimm.2015.02.004","volume":"294","author":"A Trigunaite","year":"2015","unstructured":"Trigunaite, A., Dimo, J. & Joergensen, T. N. Suppressive effects of androgens on the immune system. Cell Immunol. 294, 87\u201394 (2015).","journal-title":"Cell Immunol."},{"key":"780_CR91","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3389\/fimmu.2018.01653","volume":"9","author":"S Kadel","year":"2018","unstructured":"Kadel, S. & Kovats, S. Sex hormones regulate innate immune cells and promote sex differences in respiratory virus infection. Front. Immunol. 9, 1653 (2018).","journal-title":"Front. Immunol."},{"key":"780_CR92","unstructured":"Klein, S. L. In Sex and Gender Differences in Pharmacology (ed Regitz-Zagrosek, V.) (Springer, 2012)."},{"key":"780_CR93","doi-asserted-by":"crossref","first-page":"101450","DOI":"10.1016\/j.eclinm.2022.101450","volume":"48","author":"E Nicastri","year":"2022","unstructured":"Nicastri, E. et al. A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19. EClinicalMedicine 48, 101450 (2022).","journal-title":"EClinicalMedicine"},{"key":"780_CR94","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-020-2700-3","volume":"588","author":"T Takahashi","year":"2020","unstructured":"Takahashi, T. et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 588, 315\u2013320 (2020).","journal-title":"Nature"},{"key":"780_CR95","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","volume":"584","author":"C Lucas","year":"2020","unstructured":"Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463\u2013469 (2020).","journal-title":"Nature"},{"key":"780_CR96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008520","volume":"16","author":"Y Meng","year":"2020","unstructured":"Meng, Y. et al. Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168 severe patients. PLoS Pathog. 16, e1008520 (2020).","journal-title":"PLoS Pathog."},{"key":"780_CR97","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/cid\/ciaa351","volume":"71","author":"K Xu","year":"2020","unstructured":"Xu, K. et al. Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19). Clin. Infect. Dis. 71, 799\u2013806 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"780_CR98","doi-asserted-by":"crossref","first-page":"m1443","DOI":"10.1136\/bmj.m1443","volume":"369","author":"S Zheng","year":"2020","unstructured":"Zheng, S. et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ 369, m1443 (2020).","journal-title":"BMJ"},{"key":"780_CR99","volume":"13","author":"FA Cadegiani","year":"2021","unstructured":"Cadegiani, F. A., McCoy, J., Gustavo Wambier, C. & Goren, A. Early antiandrogen therapy with dutasteride reduces viral shedding, inflammatory responses, and time-to-remission in males with COVID-19: a randomized, double-blind, placebo-controlled interventional trial (EAT-DUTA AndroCoV Trial \u2013 Biochemical). Cureus 13, e13047 (2021).","journal-title":"Cureus"},{"key":"780_CR100","volume":"13","author":"FA Cadegiani","year":"2021","unstructured":"Cadegiani, F. A. et al. Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19: results from a randomized, double-blinded, placebo-controlled trial. Cureus 13, e13492 (2021).","journal-title":"Cureus"},{"key":"780_CR101","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jocd.13443","volume":"19","author":"A Goren","year":"2020","unstructured":"Goren, A. et al. A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. J. Cosmet. Dermatol. 19, 1545\u20131547 (2020).","journal-title":"J. Cosmet. Dermatol."},{"key":"780_CR102","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaad.2020.05.079","volume":"83","author":"CG Wambier","year":"2020","unstructured":"Wambier, C. G. et al. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The \u201cGabrin sign\u201d. J. Am. Acad. Dermatol. 83, 680\u2013682 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"780_CR103","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.annonc.2020.04.479","volume":"31","author":"M Montopoli","year":"2020","unstructured":"Montopoli, M. et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann. Oncol. 31, 1040\u20131045 (2020).","journal-title":"Ann. Oncol."},{"key":"780_CR104","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.annonc.2020.06.023","volume":"31","author":"VG Patel","year":"2020","unstructured":"Patel, V. G. et al. Does androgen deprivation therapy protect against severe complications from COVID-19? Ann. Oncol. 31, 1419\u20131420 (2020).","journal-title":"Ann. Oncol."},{"key":"780_CR105","first-page":"77","volume":"74","author":"M Lazzeri","year":"2021","unstructured":"Lazzeri, M. et al. Impact of chronic exposure to 5-\u03b1 reductase inhibitors on the risk of hospitalization for COVID-19: a case-control study in male population from two COVID-19 regional centers of Lombardy (Italy). Minerva Urol. Nefrol. 74, 77\u201384 (2021).","journal-title":"Minerva Urol. Nefrol."},{"key":"780_CR106","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/0092623X.2021.2000535","volume":"48","author":"E Durcan","year":"2021","unstructured":"Durcan, E. et al. TransCOVID: does gender-affirming hormone therapy play a role in contracting COVID-19? J. Sex. Marital. Ther. 48, 415\u2013426 (2021).","journal-title":"J. Sex. Marital. Ther."},{"key":"780_CR107","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.06.21260086","author":"FA Cadegiani","year":"2021","unstructured":"Cadegiani, F. A. et al. Proxalutamide (GT0918) reduces the rate of hospitalization in mild-to-moderate COVID-19 female patients: a randomized double-blinded Placebo-controlled two-arm parallel trial. medRxiv https:\/\/doi.org\/10.1101\/2021.07.06.21260086 (2021).","journal-title":"medRxiv"},{"key":"780_CR108","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.22.21259318","author":"FA Cadegiani","year":"2021","unstructured":"Cadegiani, F. A. et al. Efficacy of proxalutamide in hospitalized COVID-19 patients: a randomized, double-blind, Placebo-controlled, parallel-design clinical trial. medRxiv https:\/\/doi.org\/10.1101\/2021.06.22.21259318 (2021).","journal-title":"medRxiv"},{"key":"780_CR109","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.24.21261047","author":"FA Cadegiani","year":"2021","unstructured":"Cadegiani, F. A., Goren, A., Wambier, C. G. & Zimerman, R. A. Proxalutamide improves inflammatory, immunologic, and thrombogenic markers in mild-to-moderate COVID-19 males and females: an exploratory analysis of a randomized, double-blinded, placebo-controlled trial early antiandrogen therapy (EAT) with proxalutamide (The EAT-Proxa Biochemical AndroCoV-Trial). medRxiv https:\/\/doi.org\/10.1101\/2021.07.24.21261047 (2021).","journal-title":"medRxiv"},{"key":"780_CR110","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.28.21259661","author":"RA Zimerman","year":"2021","unstructured":"Zimerman, R. A. et al. Proxalutamide reduction of mortality rate in hospitalized COVID-19 patients depends on treatment duration \u2013 an exploratory analysis of the proxa-rescue AndroCoV trial. medRxiv https:\/\/doi.org\/10.1101\/2021.06.28.21259661 (2021).","journal-title":"medRxiv"},{"key":"780_CR111","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.01.21259656","author":"FA Cadegiani","year":"2021","unstructured":"Cadegiani, F. A. et al. Proxalutamide improves lung injury in hospitalized COVID-19 patients \u2013 an analysis of the radiological findings of the proxa-rescue AndroCoV trial. medRxiv https:\/\/doi.org\/10.1101\/2021.07.01.21259656 (2021).","journal-title":"medRxiv"},{"key":"780_CR112","volume":"13","author":"FA Cadegiani","year":"2021","unstructured":"Cadegiani, F. A. et al. Final results of a randomized, placebo-controlled, two-arm, parallel clinical trial of proxalutamide for hospitalized COVID-19 patients: a multiregional, joint analysis of the proxa-rescue AndroCoV trial. Cureus 13, e20691 (2021).","journal-title":"Cureus"},{"key":"780_CR113","unstructured":"Service, R. S. Too Good to be True: Doubts Swirl Around Trial that Saw 77% Reduction in COVID-19 Mortality https:\/\/www.science.org\/content\/article\/too-good-be-true-doubts-swirl-around-trial-saw-77-reduction-covid-19-mortality (2021)."},{"key":"780_CR114","doi-asserted-by":"crossref","first-page":"n2819","DOI":"10.1136\/bmj.n2819","volume":"375","author":"L Taylor","year":"2021","unstructured":"Taylor, L. Covid-19: Trial of experimental \u201ccovid cure\u201d is among worst medical ethics violations in Brazil\u2019s history, says regulator. BMJ 375, n2819 (2021).","journal-title":"BMJ"},{"key":"780_CR115","doi-asserted-by":"crossref","first-page":"668698","DOI":"10.3389\/fmed.2021.668698","volume":"8","author":"J McCoy","year":"2021","unstructured":"McCoy, J. et al. Proxalutamide reduces the rate of hospitalization for COVID-19 male outpatients: a randomized double-blinded placebo-controlled trial. Front. Med. 8, 668698 (2021).","journal-title":"Front. Med."},{"key":"780_CR116","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JU.0000000000001338","volume":"205","author":"EA Klein","year":"2021","unstructured":"Klein, E. A. et al. Androgen deprivation therapy in men with prostate cancer does not affect risk of infection with SARS-CoV-2. J. Urol. 205, 441\u2013443 (2021).","journal-title":"J. Urol."},{"key":"780_CR117","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13027-021-00406-y","volume":"16","author":"M Bringel","year":"2021","unstructured":"Bringel, M., Duarte, O., Leal, F., Argenton, J. L. P. & Carvalheira, J. B. C. Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis. Infect. Agents Cancer 16, 66 (2021).","journal-title":"Infect. Agents Cancer"},{"key":"780_CR118","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.7852","volume":"5","author":"NG Nickols","year":"2022","unstructured":"Nickols, N. G. et al. Effect of androgen suppression on clinical outcomes in hospitalized men with COVID-19: the HITCH randomized clinical trial. JAMA Netw. Open 5, e227852 (2022).","journal-title":"JAMA Netw. Open"},{"key":"780_CR119","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.eururo.2021.12.013","volume":"81","author":"K Wel\u00e9n","year":"2022","unstructured":"Wel\u00e9n, K. et al. A phase 2 trial of the effect of antiandrogen therapy on COVID-19 outcome: no evidence of benefit, supported by epidemiology and in vitro data. Eur. Urol. 81, 285\u2013293 (2022).","journal-title":"Eur. Urol."},{"key":"780_CR120","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1111\/ijd.15473","volume":"60","author":"K Yale","year":"2021","unstructured":"Yale, K. et al. Androgens and women: COVID-19 outcomes in women with acne vulgaris, polycystic ovarian syndrome, and hirsutism. Int. J. Dermatol. 60, e267\u2013e268 (2021).","journal-title":"Int. J. Dermatol."},{"key":"780_CR121","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jsxm.2020.09.013","volume":"18","author":"A Rambhatla","year":"2020","unstructured":"Rambhatla, A. et al. COVID-19 infection in men on testosterone replacement therapy. J. Sex. Med. 18, 215\u2013218 (2020).","journal-title":"J. Sex. Med."},{"key":"780_CR122","doi-asserted-by":"crossref","first-page":"154252","DOI":"10.1016\/j.metabol.2020.154252","volume":"108","author":"P Pozzilli","year":"2020","unstructured":"Pozzilli, P. & Lenzi, A. Commentary: testosterone, a key hormone in the context of COVID-19 pandemic. Metabolism 108, 154252 (2020).","journal-title":"Metabolism"},{"key":"780_CR123","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/andr.12821","volume":"9","author":"G Rastrelli","year":"2021","unstructured":"Rastrelli, G. et al. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology 9, 88\u201398 (2021).","journal-title":"Andrology"},{"key":"780_CR124","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-020-03086-z","volume":"24","author":"SP Rowland","year":"2020","unstructured":"Rowland, S. P. & O\u2019Brien Bergin, E. Screening for low testosterone is needed for early identification and treatment of men at high risk of mortality from Covid-19. Crit. Care 24, 367 (2020).","journal-title":"Crit. Care"},{"key":"780_CR125","volume":"4","author":"S Dhindsa","year":"2021","unstructured":"Dhindsa, S., Zhang, N. & McPhaul, M. J. Association of circulating sex hormones with inflammation and disease severity in patients with COVID-19. Diabetes Endocrinol. 4, e2111398 (2021).","journal-title":"Diabetes Endocrinol."},{"key":"780_CR126","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/andr.12836","volume":"9","author":"VA Giagulli","year":"2021","unstructured":"Giagulli, V. A. et al. Worse progression of COVID-19 in men: is testosterone a key factor? Andrology 9, 53\u201364 (2021).","journal-title":"Andrology"},{"key":"780_CR127","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1080\/22221751.2021.1969869","volume":"10","author":"M Schroeder","year":"2021","unstructured":"Schroeder, M. et al. High estradiol and low testosterone levels are associated with critical illness in male but not in female COVID-19 patients: a retrospective cohort study. Emerg. Microbes Infect. 10, 1807\u20131818 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"780_CR128","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027072","volume":"100","author":"IE van Zeggeren","year":"2021","unstructured":"van Zeggeren, I. E. et al. Sex steroid hormones are associated with mortality in COVID-19 patients: Level of sex hormones in severe COVID-19. Medicine 100, e27072 (2021).","journal-title":"Medicine"},{"key":"780_CR129","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijid.2021.05.042","volume":"108","author":"M Camici","year":"2021","unstructured":"Camici, M. et al. Role of testosterone in SARS-CoV-2 infection: a key pathogenic factor and a biomarker for severe pneumonia. Int. J. Infect. Dis. 108, 244\u2013251 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"780_CR130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13293-021-00407-x","volume":"12","author":"MT Pagano","year":"2021","unstructured":"Pagano, M. T. et al. Predicting respiratory failure in patients infected by SARS-CoV-2 by admission sex-specific biomarkers. Biol. Sex. Dif. 12, 63 (2021).","journal-title":"Biol. Sex. Dif."},{"key":"780_CR131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20420188211010105","volume":"12","author":"S Salciccia","year":"2021","unstructured":"Salciccia, S., Giudice, F. D., Eisenberg, M. L. & Mastroianni, C. M. Testosterone target therapy: focus on immune response, controversies and clinical implications in patients with COVID-19 infection. Ther. Adv. Endocrinol. Metab. 12, 1\u20138 (2021).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"780_CR132","doi-asserted-by":"crossref","first-page":"607179","DOI":"10.3389\/fendo.2021.607179","volume":"12","author":"YS Younis","year":"2021","unstructured":"Younis, Y. S., Skorecki, K. & Abassi, Z. The double edge sword of testosterone\u00b4s role in the COVID-19 pandemic. Front. Endocrinol. 12, 607179 (2021).","journal-title":"Front. Endocrinol."},{"key":"780_CR133","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"780_CR134","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/jmv.26259","volume":"93","author":"L Ma","year":"2021","unstructured":"Ma, L. et al. Evaluation of sex-related hormones and semen characteristics in reproductive-aged male COVID-19 patients. J. Med. Virol. 93, 456\u2013462 (2021).","journal-title":"J. Med. Virol."},{"key":"780_CR135","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s00134-022-06836-5","volume":"48","author":"CE Gebhard","year":"2022","unstructured":"Gebhard, C. E., Hamouda, N., Gebert, P., Regitz-Zagrosek, V. & Gebhard, C. Sex versus gender-related characteristics: which predicts clinical outcomes of acute COVID-19? Intensive Care Med. 48, 1652\u20131655 (2022).","journal-title":"Intensive Care Med."},{"key":"780_CR136","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein, S. L. & Flanagan, K. L. Sex differences in the immune response. Nat. Rev. Immunol. 16, 626\u2013638 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"780_CR137","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1600-0897.1996.tb00492.x","volume":"35","author":"J Szekeres-Bartho","year":"1996","unstructured":"Szekeres-Bartho, J., Faust, Z., Varga, P., Szereday, L. & Kelemen, K. The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production. Am. J. Reprod. Immunol. 35, 348\u2013351 (1996).","journal-title":"Am. J. Reprod. Immunol."},{"key":"780_CR138","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.4049\/jimmunol.1601896","volume":"198","author":"R Channappanavar","year":"2017","unstructured":"Channappanavar, R. et al. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J. Immunol. 198, 4046\u20134053 (2017).","journal-title":"J. Immunol."},{"key":"780_CR139","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257051","volume":"16","author":"R Costeira","year":"2021","unstructured":"Costeira, R. et al. Estrogen and COVID-19 symptoms: associations in women from the COVID symptom study. PLoS One 16, e0257051 (2021).","journal-title":"PLoS One"},{"key":"780_CR140","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1093\/cid\/ciaa1022","volume":"72","author":"T Ding","year":"2020","unstructured":"Ding, T. et al. Potential influence of menstrual status and sex hormones on female SARS-CoV-2 infection: a cross-sectional study from multicentre in Wuhan, China. Clin. Infect. Dis. 72, e240\u2013e248 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"780_CR141","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-020-01851-z","volume":"18","author":"U Seeland","year":"2020","unstructured":"Seeland, U. et al. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. BMC Med. 18, 369 (2020).","journal-title":"BMC Med."},{"key":"780_CR142","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmac041","author":"H Dambha-Miller","year":"2022","unstructured":"Dambha-Miller, H. et al. Mortality in COVID-19 among women on hormone replacement therapy: a retrospective cohort study. Fam. Pract. https:\/\/doi.org\/10.1093\/fampra\/cmac041 (2022).","journal-title":"Fam. Pract."},{"key":"780_CR143","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.annonc.2021.01.069","volume":"32","author":"M Montopoli","year":"2021","unstructured":"Montopoli, M. et al. Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy. Ann. Oncol. 32, 676\u2013677 (2021).","journal-title":"Ann. Oncol."},{"key":"780_CR144","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.steroids.2012.12.011","volume":"78","author":"ME Baker","year":"2013","unstructured":"Baker, M. E. What are the physiological estrogens? Steroids 78, 337\u2013340 (2013).","journal-title":"Steroids"},{"key":"780_CR145","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3389\/fimmu.2018.01332","volume":"9","author":"O Bereshchenko","year":"2018","unstructured":"Bereshchenko, O., Bruscoli, S. & Riccardi, C. Glucocorticoids, sex hormones, and immunity. Front. Immunol. 9, 1332 (2018).","journal-title":"Front. Immunol."},{"key":"780_CR146","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vph.2013.06.001","volume":"59","author":"LM Goddard","year":"2013","unstructured":"Goddard, L. M., Ton, A. N., Org, T., Mikkola, H. K. & Iruela-Arispe, M. L. Selective suppression of endothelial cytokine production by progesterone receptor. Vasc. Pharmacol. 59, 36\u201343 (2013).","journal-title":"Vasc. Pharmacol."},{"key":"780_CR147","doi-asserted-by":"crossref","first-page":"100109","DOI":"10.1016\/j.endmts.2021.100109","volume":"5","author":"SB Shah","year":"2021","unstructured":"Shah, S. B. COVID-19 and progesterone: part 1. SARS-CoV-2, progesterone and its potential clinical use. Endocr. Metab. Sci. 5, 100109 (2021).","journal-title":"Endocr. Metab. Sci."},{"key":"780_CR148","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.chest.2021.02.024","volume":"160","author":"S Ghandehari","year":"2021","unstructured":"Ghandehari, S., Matusov, Y., Pepkowitz, S., Stein, D. & Kaderi, T. Progesterone in addition to standard of care alone in the treatment of men hospitalized with moderate to severe COVID-19: a randomized, controlled, pilot trial. Chest Infect. 160, 74\u201384 (2021).","journal-title":"Chest Infect."},{"key":"780_CR149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/000456328502200101","volume":"22","author":"P Wood","year":"1985","unstructured":"Wood, P., Groom, G., Moore, A., Ratcliffe, W. & Selby, C. Progesterone assays: guidelines for the provision of a clinical biochemistry service. Ann. Clin. Biochem. 22, 1\u201324 (1985).","journal-title":"Ann. Clin. Biochem."},{"key":"780_CR150","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijid.2020.04.065","volume":"95","author":"X Qiancheng","year":"2020","unstructured":"Qiancheng, X., Jian, S. & Lingling, P. Coronavirus disease 2019 in pregnancy. Int. J. Infect. Dis. 95, 376\u2013383 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"780_CR151","doi-asserted-by":"crossref","first-page":"m2107","DOI":"10.1136\/bmj.m2107","volume":"369","author":"M Knight","year":"2020","unstructured":"Knight, M., Bunch, K. & Kaler, J. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ 369, m2107 (2020).","journal-title":"BMJ"},{"key":"780_CR152","doi-asserted-by":"crossref","first-page":"769","DOI":"10.15585\/mmwr.mm6925a1","volume":"69","author":"S Ellington","year":"2020","unstructured":"Ellington, S. et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-June 7, 2020. Morb. Mortal. Wkly. Rep. 69, 769\u2013775 (2020).","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"780_CR153","doi-asserted-by":"crossref","first-page":"E540","DOI":"10.1503\/cmaj.202604","volume":"193","author":"SQ Wei","year":"2021","unstructured":"Wei, S. Q., Bilodeau-Bertrand, M., Liu, S. & Auger, N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. Can. Med. Assoc. J. 193, E540\u2013E548 (2021).","journal-title":"Can. Med. Assoc. J."},{"key":"780_CR154","volume":"382","author":"L Chen","year":"2020","unstructured":"Chen, L. et al. Clinical characteristics of pregnant women with Covid-19 in Wuhan, China. N. Engl. J. Med. 382, e100 (2020).","journal-title":"N. Engl. J. Med."},{"key":"780_CR155","doi-asserted-by":"crossref","first-page":"651752","DOI":"10.3389\/fgwh.2021.651752","volume":"2","author":"L Newson","year":"2021","unstructured":"Newson, L. et al. Sensitive to infection but strong in defense \u2014 female sex and the power of oestradiol in the COVID-19 pandemic. Front. Glob. Womens Health 2, 651752 (2021).","journal-title":"Front. Glob. Womens Health"},{"key":"780_CR156","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/CDLI.9.4.747-752.2002","volume":"9","author":"BH Natelson","year":"2002","unstructured":"Natelson, B. H., Haghighi, M. H. & Ponzio, N. M. Evidence for the presence of immune dysfunction in chronic fatigue syndrome. Clin. Vaccine Immunol. 9, 747\u2013752 (2002).","journal-title":"Clin. Vaccine Immunol."},{"key":"780_CR157","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.11.21255153","author":"PK Mishra","year":"2021","unstructured":"Mishra, P. K. et al. Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells. medRxiv https:\/\/doi.org\/10.1101\/2021.04.11.21255153 (2021).","journal-title":"medRxiv"},{"key":"780_CR158","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/resp.14003","volume":"5","author":"PA Wark","year":"2021","unstructured":"Wark, P. A. et al. ACE2 expression is elevated in airway epithelial cells from older and male healthy individuals but reduced in asthma. Respirology 5, 442\u2013451 (2021).","journal-title":"Respirology"},{"key":"780_CR159","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bbrc.2020.10.066","volume":"538","author":"DC Sarver","year":"2020","unstructured":"Sarver, D. C. & Wong, G. W. Obesity alters Ace2 and Tmprss2 expression in lung, trachea, and esophagus in a sex-dependent manner: Implications for COVID-19. Biochem. Biophys. Res. Commun. 538, 92\u201396 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"780_CR160","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12931-020-01605-8","volume":"22","author":"NZ Kermani","year":"2021","unstructured":"Kermani, N. Z., Song, W. J., Badi, Y., Versi, A. & Guo, Y. Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthma. Respri. Res. 22, 10 (2021).","journal-title":"Respri. Res."},{"key":"780_CR161","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41392-021-00513-7","volume":"6","author":"D Okuwan-Duodu","year":"2021","unstructured":"Okuwan-Duodu, D., Lim, E. C., You, S. & Engman, D. M. TMPRSS2 activity may mediate sex differences in COVID-19 severity. Signal. Transduct. Target. Ther. 6, 100 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"780_CR162","doi-asserted-by":"crossref","first-page":"10087","DOI":"10.18632\/aging.103415","volume":"12","author":"R Asselta","year":"2020","unstructured":"Asselta, R. & Paraboschi, E. M. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging 12, 10087\u201310098 (2020).","journal-title":"Aging"},{"key":"780_CR163","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.devcel.2020.05.012","volume":"53","author":"JC Smith","year":"2020","unstructured":"Smith, J. C. et al. Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract.Dev. Cell 53, 514\u2013529 (2020).","journal-title":"Dev. Cell"},{"key":"780_CR164","volume":"11","author":"IT Lee","year":"2020","unstructured":"Lee, I. T. et al. ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs. Nat. Commun. 11, 5453 (2020).","journal-title":"Nat. Commun."},{"key":"780_CR165","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/infdis\/jiab383","volume":"224","author":"K Li","year":"2021","unstructured":"Li, K., Wohlford-Lenane, C., Bartlett, J. A. & McCray, P. B. Inter-subject variation in ACE2 protein expression in human airway epithelia and its relationship to severe acute respiratory syndrome coronavirus 2. J. Infect. Dis. 224, 1357\u20131361 (2021).","journal-title":"J. Infect. Dis."},{"key":"780_CR166","volume":"15","author":"H Barker","year":"2020","unstructured":"Barker, H. & Parkkila, S. Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2. PLoS One 15, e0240647 (2020).","journal-title":"PLoS One"},{"key":"780_CR167","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10096-020-04089-y","volume":"40","author":"F Piva","year":"2021","unstructured":"Piva, F., Sabanovic, B., Cecati, M. & Giulietti, M. Expression and co-expression analyses of TMPRSS2, a key element in COVID-19. Eur. J. Clin. Microbiol. Infect. Dis. 40, 451\u2013455 (2021).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"780_CR168","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-021-05389-0","volume":"22","author":"NG Nickols","year":"2021","unstructured":"Nickols, N. G. et al. Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial. Trials 22, 431 (2021).","journal-title":"Trials"},{"key":"780_CR169","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","volume":"20","author":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection.","year":"2020","unstructured":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis. 20, e192\u2013e197 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"780_CR170","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053684","volume":"11","author":"D Lovre","year":"2021","unstructured":"Lovre, D. et al. Acute estradiol and progesterone therapy in hospitalised adults to reduce COVID-19 severity: a randomised control trial. BMJ Open 11, e053684 (2021).","journal-title":"BMJ Open"},{"key":"780_CR171","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04539626 (2022)."},{"key":"780_CR172","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04475601 (2021)."},{"key":"780_CR173","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04652765 (2021)."},{"key":"780_CR174","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04359329 (2020)."},{"key":"780_CR175","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04374279 (2021)."},{"key":"780_CR176","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04509999 (2021)."},{"key":"780_CR177","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04853927 (2022)."},{"key":"780_CR178","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04853069 (2021)."},{"key":"780_CR179","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04578236 (2020)."},{"key":"780_CR180","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04623385 (2020)."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-022-00780-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-022-00780-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-022-00780-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T14:05:04Z","timestamp":1733493904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-022-00780-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":180,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["780"],"URL":"https:\/\/doi.org\/10.1038\/s41574-022-00780-6","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]},"assertion":[{"value":"10 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}